Form 4: Lexeo CDO Sells Shares for Tax Obligations

Lexeo Therapeutics' Chief Development Officer, Sandi See Tai, sold 382 shares of common stock to cover tax obligations related to restricted stock units.

Summary

• Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, Inc. (LXEO), sold 382 shares of common stock.
• The transaction occurred on August 18, 2025, at a price of $4.668 per share.
• The sale was conducted to cover tax obligations arising from the release of restricted stock units (RSUs).
• Following this transaction, Sandi See Tai beneficially owns 58,860 shares of Lexeo Therapeutics common stock, which includes 49,138 RSUs.

Sentiment

Score: 5

Explanation: The transaction is a routine sale to cover tax obligations on RSU vesting, which is a common practice and does not indicate a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Minimal direct impact on shareholders, as the sale of shares by the Chief Development Officer was for routine tax obligations related to RSU vesting.

Key Dates

Recommendation

The reported transaction is a routine sale of shares by an executive to cover tax obligations associated with the vesting of restricted stock units. This type of transaction is common and does not typically reflect a change in the executive's confidence in the company's long-term prospects or fundamental performance. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

Lexeo Therapeutics, LXEO, Form 4, insider trading, stock sale, restricted stock units, RSU, Chief Development Officer, Sandi See Tai